11 Most Undervalued Small-Cap Stocks to Buy According to Analysts

Page 4 of 10

7. Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)

Forward P/E Ratio as of July 8: 8.84

Market Capitalization as of July 8: $1.88 billion

Number of Hedge Fund Holders: 27

Average Upside Potential as of July 8: 49.62%

Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is one of the most undervalued small-cap stocks to buy according to analysts. On June 11, Harmony Biosciences Holdings presented promising preclinical pharmacological data for BP1.15205, which is an investigational orexin 2 receptor (OX2R) agonist, at the 39th Annual Meeting of the Associated Professional Sleep Societies/APSS “SLEEP” in Seattle.

The data showed significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1. Narcolepsy is a chronic neurological disease affecting ~170,000 Americans, primarily characterized by excessive daytime sleepiness/EDS and cataplexy, along with other manifestations of REM sleep dysregulation.

The disease is often caused by the loss of hypocretin/orexin, a neuropeptide crucial for sleep-wake stability. BP1.15205 features a new and unique chemical scaffold optimized for high potency, which showed statistically significant wake-promoting effects at very low oral doses in the transgenic mouse model. These findings support dosing flexibility to potentially treat all 3 central disorders of hypersomnolence at low doses, which could offer an optimized benefit-risk profile.

Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops & commercializes therapies for patients with rare & other neurological diseases in the US.

Page 4 of 10